• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » Two Updates on Pimavenserin [60 Sec Psych]

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts and Spotify.

Two Updates on Pimavenserin [60 Sec Psych]

October 21, 2020

Last April we reported on Pimavenserin – Nuplazid – the novel antipsychotic that’s FDA approved in psychosis related to parkinson’s disease. In that article we mentioned a randomized controlled trial from Mass General – the CLARITY trial - that showed promising augmentation effects when Pimavenserin was added to an antidepressant in major depressive disorder. Now comes a secondary analysis of that study, which found a significant reduction in anxiety symptoms as well. [Link and Link]


Published On: 10/21/2020


Duration: 3 minutes, 9 seconds


Transcript:


Last April we reported on Pimavenserin – Nuplazid – the novel antipsychotic that’s FDA approved in psychosis related to parkinson’s disease. In that article we mentioned a randomized controlled trial from Mass General – the CLARITY trial - that showed promising augmentation effects when Pimavenserin was added to an antidepressant in major depressive disorder. Now comes a secondary analysis of that study, which found a significant reduction in anxiety symptoms as well. 

This was a large, 5 week, randomized placebo controlled trial of 151 patients with treatment resistant depression who had failed two trials of antidepressants. The original study showed significant improvement on the Hamilton depression scale when  Pimavenserin was added to the antidepressant. This secondary analysis looked at the anxiety/somatization factor of the scale and also saw improvement – with moderate effect size of 0.6. The dose of pimavanserin was 34 mg a day.

The results are encouraging, but need replication, and in the case of anxiety they are only post-hoc results.

Separately, Pimavenserin is pursuing FDA approval in psychosis related to dementia. The company submitted their application to the FDA after their phase 3 HARMONY trial showed that Pimavenserin might reduce the risk of relapse into psychosis in patients with dementia due to various causes – alzheimers, Lewy Body, Parkinson’s, Vascular, and frontal-temporal dementia. That’s encouraging, as those of you who are studying for your board exams will probably recall that antipsychotics are relatively contraindicated in Lewy Body dementia.

Earlier, a phase II study had shown reduction in psychosis in dementia with Pimavenserin compared to placebo after 6 weeks. The new study is a discontinuation study. 351 patients with dementia related psychosis were randomized to stay on or discontinue Pimavenserin after 12 weeks on the drug. The risk of relapse into psychosis was 3 times higher in the ones who came off Pimavenserin.

Got feedback? Take the podcast survey.

Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.